Quality of life considerations in the treatment of metastatic hormone-sensitive prostate cancer
2019; Elsevier BV; Volume: 20; Issue: 11 Linguagem: Inglês
10.1016/s1470-2045(19)30628-x
ISSN1474-5488
AutoresSuzanne K. Chambers, Mark Frydenberg, Jeff Dunn,
Tópico(s)Prostate Cancer Diagnosis and Treatment
ResumoGlobally, the incidence and prevalence of prostate cancer are increasing, with more than 1·2 million men now estimated to be diagnosed every year. 1 Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424 Crossref PubMed Scopus (36643) Google Scholar Although in countries such as the USA and Australia, most men will be diagnosed with localised disease, 2 Evans SM Tikellis G Brooks A et al. Prostate Cancer Outcomes Registry: Australia and New Zealand report 2018. Reporting on data 2015–2016. Monash University & The Movember Foundation, Melbourne, VIC2018 Google Scholar the burden of metastatic disease is still substantial and unevenly distributed. 3 Dasgupta P Baade PD Aitken JF Ralph N Chambers SK Dunn J Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Front Oncol. 2019; 9: 238 Crossref PubMed Scopus (25) Google Scholar Furthermore, men with advanced or metastatic disease experience poorer quality of life, and higher psychological morbidity and risk of suicide than men with localised disease. 4 Smith DP Calopedos R Bang A et al. Increased risk of suicide in New South Wales men with prostate cancer: analysis of linked population-wide data. PLoS One. 2018; 13e0198679 PubMed Google Scholar , 5 Zajdlewicz L Hyde MK Lepore SJ Gardiner RA Chambers SK Health-related quality of life after the diagnosis of locally advanced or advanced prostate cancer: a longitudinal study. Cancer Nurs. 2017; 40: 412-419 Crossref PubMed Scopus (19) Google Scholar Therefore, for these men, a consideration of the patient experience is crucial. In The Lancet Oncology, Neeraj Agarwal and colleagues 6 Agarwal N McQuarrie K Bjartell A et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019; (published online Sept 29)https://doi.org/10.1016/S1470-2045(19)30620-5 Summary Full Text Full Text PDF PubMed Scopus (28) Google Scholar present patient-reported outcomes from the TITAN study, providing insight into the effects on quality of life when apalutamide is used as an adjunctive therapy to androgen deprivation in men with metastatic castration-sensitive prostate cancer. The question of treatment burden is important to men diagnosed with metastatic castration-sensitive prostate cancer, for whom overall survival, as well as radiographic progression-free survival and delay to cytotoxic therapy, are critical. But do treatments that improve these outcomes come at a cost of compromised quality of life? Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyApalutamide with ADT is a well-tolerated and effective option for men with metastatic castration-sensitive prostate cancer. The combination significantly improves survival outcomes compared with ADT alone while maintaining HRQOL despite additive androgen blockade. Full-Text PDF
Referência(s)